Patents - stay tuned to the technology

Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Enhanced absorption of therapeutic material internally using iontophoretic treatment

Subclass of:

604 - Surgery

604019000 - MEANS FOR INTRODUCING OR REMOVING MATERIAL FROM BODY FOR THERAPEUTIC PURPOSES (E.G., MEDICATING, IRRIGATING, ASPIRATING, ETC.)

604048000 - Treating material introduced into or removed from body orifice, or inserted or removed subcutaneously other than by diffusing through skin

604500000 - Method

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
604501000 Enhanced absorption of therapeutic material internally using iontophoretic treatment 72
20080215032Minimizing Metal Toxicity During Electroporation Enhanced Delivery of Polynucleotides - Methods are provided for introducing a polynucleotide into healthy tissue and generating a pulsed electric field in the tissue via invasive electrodes, resulting in enhanced delivery of the polynucleotide into cells of the tissue, while minimizing local side effects to the electroporated tissue and systemic side effects to the electroporated organism due to metal contaminants released from said electrodes. In one embodiment, the invention methods Use electrodes of gold, gold alloys, or other metal that minimize the introduction of toxic amounts of the metal into electroporated tissue. In other embodiments, the invention methods are utilized for the gene therapy by administering DNA to cells of suitable target tissue, and for the induction of an immune response by administration of a DNA vaccine.09-04-2008
20080262468System and Method for the Simultaneous Bilateral Treatment of Target Tissues Within the Ears Using a Guide Block Structure - Systems and methods for treating a patient having a head with a first ear and a second ear, function by mounting a support structure to the head of the patient; aligning the support structure with a target tissue in an ear canal of the first ear; stabilizing the support structure relative to the target tissue by injecting a material into the canal and hardening the material; and actuating a device while the device is supported by the support system so that the device therapeutically remodels the target tissue of the first ear.10-23-2008
20090076479DEVICE FOR TREATMENT OF BARRIER MEMBRANES - The present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; and a carrier; wherein the power source is in electric communication with the first conductive electrode and the second conductive electrode, wherein the first conductive electrode and the second conductive electrode are in ionic communication with the carrier, and wherein the carrier is in communication with the barrier membrane contacting surface.03-19-2009
20090088721Enhanced retinal delivery of a nucleic acid through iontophoresis - The present invention provides a device and a method for the enhanced retinal delivery of nucleic acid therapeutics utilizing iontophoresis to evoke a transient elongation of the Müller Cells of a mammalian eye. The enhanced retinal deposition can be achieved by either a topical application, subconjunctival, or an intravitreal injection of the nucleic acid composition followed by, preceded by, or administered simultaneously with the iontophoretic application. The present invention thus provides a particularly advantageous method for the treatment of ocular diseases comprising the in vivo administration of a nucleic acid capable of alleviating the symptoms of a disease, the delivery of the nucleic acid being enhanced by using iontophoresis. This method can be applied particularly to the diseases of the retina resulting from an alteration of a gene expression and/or the over-expression of particular growth factors. The diseases include, but are not limited to, human ocular retinopathies including, neovascular diseases (Age-Related Macular Edema, Diabetic Retinopathies, Diabetic Macular Edema, etc.) and inherited retinopathies such as retinitis pigmentosa.04-02-2009
20090131905Microneedle devices and methods of manufacture and use thereof - Microneedle devices are provided for transport of therapeutic and biological molecules across tissue barriers and for use as microflameholders. In a preferred embodiment for transport across tissue, the microneedles are formed of a biodegradable polymer. Methods of making these devices, which can include hollow and/or porous microneedles, are also provided. A preferred method for making a microneedle includes forming a micromold having sidewalls which define the outer surface of the microneedle, electroplating the sidewalls to form the hollow microneedle, and then removing the micromold from the microneedle. In a preferred method of use, the microneedle device is used to deliver fluid material into or across a biological barrier from one or more chambers in fluid connection with at least one of the microneedles. The device preferably further includes a means for controlling the flow of material through the microneedles. Representative examples of these means include the use of permeable membranes, fracturable impermeable membranes, valves, and pumps.05-21-2009
20090143761AGENT DELIVERY SYSTEM AND USES OF SAME - The use of an automated, controllable, and affixable pulsatile for treating diseases, having an automated controller for controlling the delivery of drug to a patient, an agent delivery reservoir containing an agent operatively connected to the automated controller, a reservoir controller operatively connected to the automated controller and the reservoir for controlling the delivery of agent to a patient, and a feedback control operatively connected to the automated controller for providing feedback with regard to the drug requirements of the patient for use in treating diseases.06-04-2009
20090171313IONTOPHORESIS DEVICE HAVING AN ACTIVE ELECTRODE UNIT - An iontophoresis device transdermally administers an active agent, such as a drug ion, to a biological interface of an organism. The iontophoresis device includes a first electrode assembly having a first electrode member, which is electrically coupled to a terminal, of a main electric power source, having a first polarity that is the same polarity as that of a drug ion. The iontophoresis device includes a drug solution reservoir arranged in an electric field generated by the first electrode member and holding a drug, a counter electrode assembly electrically coupled to another terminal (of the main electric power source) having a second polarity that is opposite to the first polarity, and a vibrating portion having an ultrasonic oscillator for oscillating an ultrasonic wave and an ultrasonic vibrator vibrating due to the ultrasonic wave supplied from the ultrasonic oscillator. The ultrasonic vibrator is provided in the vicinity of the active electrode assembly.07-02-2009
20090221985SYSTEM FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF POLYMERIC AGENTS AND METHODS OF USE THEREOF - A system for iontophoretic transdermal delivery of a non-peptidic polymeric cosmetic or therapeutic agent or of a polypeptide useful for delivery of high molecular weight cosmetic or therapeutic agents. Particularly, the present invention relates to a system that includes an iontophoresis device and a pharmaceutical composition of a non-peptidic polymeric cosmetic or therapeutic agent together with a peptide, polypeptide or protein and a pharmaceutically acceptable carrier having a pH below or above the isoelectric pH of the peptide, polypeptide or protein.09-03-2009
20090240231Subdermal material delivery device - A method may include placing a first device on a first side of a skin portion of a subject and transferring a material through the skin portion of the subject from the first device to a subdermal second device disposed on a second side of the skin portion of the subject.09-24-2009
20090264855Method and Device for Transdermal Electrotransport Delivery of Fentanyl and Sufentanil - The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10-22-2009
20100004623Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation - Electroporation devices and methods for use in the treatment of complications, such as thrombosis, stenotic segments, or infections, associated with an arteriovenous graft or fistula are provided. The devices include at least two electrodes. The electrodes are adapted to be positioned near the target zone of complication for applying electrical pulses and thereby causing electroporation. In a preferred embodiment, the electroporation pulses are sufficient to subject substantially all cells within the target zone to irreversible electroporation without creating a thermally damaging effect.01-07-2010
20100010467GROWTH HORMONE RELEASING HORMONE TREATMENT TO DECREASE CHOLESTEROL LEVELS - This invention is related to compositions and methods for decreasing cholesterol levels in a subject. The method utilizes a nucleic acid expression construct that encodes a growth-hormone-releasing-hormone (“GHRH”) that is delivered into a tissue of the subject, wherein, GHRH is expressed in vivo in the subject.01-14-2010
20100016828Drug Delivery System and Method - A method for delivering a therapeutic agent to a predetermined location in a host is disclosed, wherein a liposome-encapsulated therapeutic agent is administered to the host, and an electrical field which encompasses a predetermined region within the host is established, such that as the liposome-encapsulated agent is exposed to the electrical field the release of the agent from the liposome to the predetermined region is enhanced.01-21-2010
20100191216INDICATIONS FOR LOCAL TRANSPORT OF ANAESTHETIC AGENTS BY ELECTROTRANSPORT DEVICES - The use of an iontophoresis electrode assembly for delivery of a drug formulation is described. The drug formulation includes an anaesthetic and a vasoconstrictor. It is administered to a patient prior to a procedure to produce clinically acceptable depth and duration of dermal anaesthesia at the portion of skin to subject to a painful procedure or to reduce or eliminate pain. The procedure is one selected from the group consisting of venipuncture, IV cannulation, needle aspirations, body piercings, blood donations, electrolysis, tattoo removal, tattoo application, injections, dermabrasion, skin peeling, high velocity particle ablation, pace maker implantation, pace maker replacement, epidural puncture, lumbar puncture, regional nerve blocks, skin harvesting, small skin incisions, skin biopsies, circumcisions or excisions. The iontophoresis electrode assembly may also be used to reduce or temporarily eliminate neuropathic pain.07-29-2010
20100331810Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent - Embodiments of the invention provide a device, system and method for the transdermal iontophoretic delivery of therapeutic agents. One embodiment provides a method comprising applying first and second patches to the skin. The first patch comprises a delivery electrode, a therapeutic agent and two lateral electrodes. The second patch comprises at least a delivery electrode. A first current is delivered to the skin and create a first driving force to transport the agent into the skin. A second current is delivered to the skin and creates a second driving force to oscillate the agent in a direction substantially parallel to the skin. The agent is transported across the skin using the first driving force to propel the agent into the skin, and the second driving force to oscillate the agent substantially parallel to the skin surface so that it is sieved through pathways of least diffusional resistance in the skin.12-30-2010
20100331811CORROSION RESISTANT ELECTRODES FOR IONTOPHORETIC TRANSDERMAL DELIVERY DEVICES AND METHODS OF USE - Embodiments of the invention provide electrode assemblies and associated methods for the iontophoretic transdermal delivery of therapeutic agents. Many embodiments provide a corrosion resistant electrode for the iontophoretic transdermal delivery of various therapeutic agents. Such embodiments allow for the iontophoretic transdermal delivery of therapeutic agents such as iron compounds for prolonged periods without any substantial corrosion of the electrode, impedance increases or discoloration or irritation of the skin. Embodiments of the invention are particularly useful for the long term treatment of various chronic medical conditions such as iron deficient anemia.12-30-2010
20100331812Pharmaceutical Formulations for Iontophoretic Delivery of an Immunomodulator - The present invention describes pharmaceutical formulations and methods suitable for iontophoretic delivery of the formulations to a subject. The formulations comprise an immunomodulator, such as imiquimod, and optionally include various agents and excipients. The formulations can be used as a treatment for skin diseases and conditions such as actinic keratosis, basal cell carcinoma and genital warts. The short term iontophoretic delivery of the formulations results in the creation of a depot effect in the skin of the subject, allowing for a sustained delivery. The shortened delivery time minimizes local side effects at the application site.12-30-2010
20110066134Controlling Drug Transport and Current in Iontophoretic Onychomycosis Treatment - Pharmaceutical drugs and formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of an anti-fungal drug to at least one body surface, such as a nail, are described. Also described are pharmaceutical formulations suitable for iontophoresis comprising terbinafine and methods for administering terbinafine to a body surface via iontophoresis. When the drug source is introduced into the nail using a mask, terbinafine concentrations in peripheral areas of nail following iontophoretic treatment are less than drug concentrations directly under the mask. Further, differences in delivered drug concentrations is effectuated by creating drug delivery gradients. Drug can be delivered to dissimilar tissues based on different transfer efficiencies exhibited by the dissimilar tissues, resulting in higher percentage delivery in one tissue vs. another tissue.03-17-2011
20110071491Current Concentration System and Method for Electrokinetic Delivery of Medicaments - An electrokinetic apparatus to apply medicament to a treatment site of a mammalian user, the apparatus including: a flux concentrator including an active electrode and a counter electrode adapted to be applied to the surface of a toenail or fingernail of the user, and a medicament matrix adjacent the active electrode and arranged to be sandwiched between the active electrode and nail.03-24-2011
20110118695Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject - A device, a system, or a method is described for treating a disease or a condition of one or more joints of articulating bone in a mammalian subject. The device provides one or more medicaments to one or more joints of the mammalian subject. A device is described that includes one or more substrates configured to contact one or more body contours in proximity to one or more joints of articulating bone of a mammalian subject; one or more sensors configured to monitor movement of the one or more body contours; and one or more applicators supported by the one or more substrates and configured to respond to the movement of the one or more body contours by injecting one or more medicaments to the one or more joint tissues of the mammalian subject.05-19-2011
20110137284DEVICES FOR MATERIAL DELIVERY, ELECTROPORATION, AND MONITORING ELECTROPHYSIOLOGICAL ACTIVITY - The invention relates generally to devices for material delivery, electroporation and monitoring electrophysiological activity. In particular, the present invention provides devices and systems configured to deliver therapeutic compositions, to provide electroporation to increase therapeutic efficiency, and to monitor electrophysiological activity, for example, before and after treatment.06-09-2011
20110190724PROCESS AND SYSTEM FOR IONTOPHORETIC WRINKLE REDUCTION - A method and system for wrinkle reduction. The method includes the steps of positioning and applying a patch to skin of a consumer and adhesively securing the patch to the skin. A chemical composition on the patch includes both active ingredients and adhesive. A pair of electrodes are connected to a battery-driven, microprocessor-based controller. A current is applied through the electrodes in the patch for a selected time. The chemical composition in the patch is propelled into the consumer through use of the current in order to relax the skin of the consumer. The patch is removed and any residue of the chemical composition is massaged into the skin.08-04-2011
20110213330TRANSDERMAL METHODS AND SYSTEMS FOR THE DELIVERY OF ANTI-MIGRAINE COMPOUNDS - Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.09-01-2011
20120165782 PHARMACEUTICAL COMPOSITION OF AN IONTOPHORESIS - It is an object of the present inventions to produce a pharmaceutical composition for the iontophoresis wherein a drug stability is excellent, and it is easy to blend and fill up when manufactured and it is possible to manufacture at low cost. A pharmaceutical composition for an iontophoresis according to the present invention, is characterized in that the composition contains a nonionic synthetic polymer, betamethasone sodium phosphate and solvent. Furthermore, in a preferred embodiment of a pharmaceutical composition for an iontophoresis according to the present invention, the composition is characterized in that the nonionic synthetic polymer is polyvinyl alcohol (PVA). Furthermore, in a preferred embodiment of a pharmaceutical composition for an iontophoresis according to the present invention, the composition is characterized in that the mixing amount of the polyvinyl alcohol (PVA) is 0.5 to 30.0 percent by weight.06-28-2012
20120323214ALZHEIMER'S DISEASE TREATMENT WITH MULTIPLE THERAPEUTIC AGENTS DELIVERED TO THE OLFACTORY REGION THROUGH A SPECIAL DELIVERY CATHETER AND IONTOPHORESIS - This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE.12-20-2012
20130023850SYSTEM AND METHOD FOR BIPHASIC TRANSDERMAL IONTOPHORETIC DELIVERY OF THERAPEUTIC AGENTS FOR THE CONTROL OF ADDICTIVE CRAVINGS - Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., nicotine compounds for the treatment of nicotine cravings from tobacco use. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient.01-24-2013
20130060227APPARATUS AND METHOD FOR DELIVERING A THERAPEUTIC AGENT TO OCULAR TISSUE - A method is provided for delivering at least one therapeutic agent to an ocular tissue of a subject. The method includes providing an apparatus including at least one electrode, a medicament layer including at least one therapeutic agent, an electrical signal source, and logic configured to control the electrical signal source. The at least one electrode has oppositely disposed first and second dome-shaped major surfaces. The medicament layer is disposed on at least a portion of the second major surface. The electrical signal source is electrically connected to the at least one electrode. At least one portion of the first major surface is placed into contact with the ocular tissue so that the at least one portion substantially conforms to the contour of the ocular tissue. The electrical signal source provides a signal having certain characteristics to motivate the at least one therapeutic agent into the ocular tissue.03-07-2013
20130066296TOLERABLE AND MINIMALLY INVASIVE SKIN ELECTROPORATION DEVICE - A novel electroporation device for the delivery of vaccines that is both effective in generating a protective immune response and tolerable delivery to a subject (or near painless); and also methods of using same device to vaccinate a subject against a variety of infectious diseases and types of cancer in a near painless.03-14-2013
20130072899Pharmaceutical Formulations for Iontophoretic Delivery of Gallium - Pharmaceutical formulations suitable for iontophoresis thereof that provide enhanced iontophoretic delivery of gallium to at least one body surface are described and methods for administering gallium to a body surface via iontophoresis. In one embodiment, the body surface is human skin.03-21-2013
20130123744METHOD AND APPARATUS FOR THE DELIVERY OF POLYNUCLEOTIDE CANCER VACCINES TO MAMMALIAN SKIN - The invention provides a method and apparatus for the delivery of polynucleotide cancer vaccines to increase T cell response and reduce pain due to long electric waveform application and muscle contractions. The method includes the steps of: (a.) administering a polynucleotide cancer vaccine into the skin at an administration site, (b.) applying a needle electrode to the skin in the vicinity of the administration site, and (c.) applying a sequence of at least three electrical waveforms to deliver the polynucleotide cancer vaccine into skin cells by electroporation. The sequence has at least one of the following characteristics {1} at least two of the waveforms differ in amplitude, {2} at least two of the waveforms differ in width, and (3) a first waveform interval for a first set of two of the waveforms is different from a second waveform interval for a second set of two of the waveforms.05-16-2013
20130150822METHOD FOR INCREASING THE PERMEABILITY OF AN EPITHELIAL BARRIER - Disclosed are nanotopography-based methods and devices for interacting with a component of epithelial tissue and increasing the permeability of the tissue. Devices include structures fabricated on a surface to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Microneedles may be beneficially utilized for delivery of an agent to a cell or tissue. Devices may be utilized to directly or indirectly alter cell behavior through the interaction of a fabricated nanotopography with the components of epithelial tissue.06-13-2013
20130158502METHOD OF INHIBITING ANGIOGENESIS OR INVASION OR FORMATION OF METASTASES - A method of treating a mammal with a tumor by decreasing intratumoral vessels associated with tumor or inhibiting formation of new intratumoral vessels includes injecting tumor with therapeutically effective amount of expression plasmid including polynucleotide coding for therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked coding sequence, wherein polynucleotide sequence is operably linked to promoter or expression control sequence, followed by application of electric pulses to site of injection in tumor or injecting muscle of mammal with therapeutically effective amount of expression plasmid including polynucleotide coding for therapeutic peptide consisting of SEQ ID NO: 2 absent any operably linked coding sequence, wherein polynucleotide sequence is operably linked to promoter or expression control sequence, followed by applying electric pulses to site of injection in muscle of mammal, whereby expression of SEQ ID NO: 2 decreases intratumoral vessels associated with tumor, or formation of new intratumoral vessels therein.06-20-2013
20130172847Compositions for Providing Vitamin D Year Round and Uses Thereof - Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed.07-04-2013
20130172848IMMUNOLOGICALLY MODIFIED CARBON NANOTUBES FOR CANCER TREATMENT - A method for constructing a compound of immunologically modified nanotubes and method for using the compound to deliver immunoadjuvants to tumor cells and to produce targeted, synergistic photophysical and immunological reactions for cancer treatment. To prepare the immunologically modified nanotubes, carbon nanotubes are dissolved in a solution of glycated chitosan, an immunostimulant, hence using glycated chitosan as a surfactant for rendering the aqueous solution of nanotubes stable. The compound can be used for treatment of cancer. The method includes steps of intratumorally administering immunologically modified nanotubes and administering laser irradiation of the target tumor. The nanotube serves as a carrier to deliver immunoadjuvants to the tumor cells and serves as a light-absorbing agent in a cell body of a tumor in a host. Upon laser irradiation of target tumor cells, immunologically modified nanotubes inside the tumor cells can produce spatially and temporally synchronized photothermal and immunological reactions for cancer treatment.07-04-2013
20130178819TREATING BACTERIA WITH ELECTRIC FIELDS - Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time at particular frequencies with particular filed strengths. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like bacteria, but does not harm normal cells that are not dividing. Since the vulnerability of the dividing cells is strongly related to the alignment between the long axis of the dividing cells and the lines of force of the electric field, improved results can be obtained when the field is sequentially imposed in different directions.07-11-2013
20130178820TREATING BACTERIA WITH ELECTRIC FIELDS - Cells that are in the process division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time at particular frequencies with particular filed strengths. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like bacteria, but does not harm normal cells that are not dividing. Since the vulnerability of the dividing cells is strongly related to the alignment between the long axis of the dividing cells and the lines of force of the electric field, improved results can be obtained when the field is sequentially imposed in different directions.07-11-2013
20130178821DEVICE AND METHOD FOR CORNEAL DELIVERY OF RIBOFLAVIN BY IONTOPHORESIS FOR THE TREATMENT OF KERATOCONUS - Ocular iontophoresis device and method for delivering any ionized drug solution to the cornea includes: a reservoir containing a solution suitable to be positioned on the eye; an active electrode disposed in or on the reservoir; and a passive electrode suitable to be placed on the skin of the subject, elsewhere on the body; elements for irradiating the cornea surface with suitable light for obtaining corneal cross-linking after the drug delivery; wherein the reservoir and the active electrode are transparent to UV light and/or visible light and/or IR light. The method includes: positioning the iontophoretic device on the eye to be treated; driving the solution by a cathodic current applied for 0.5 to 5 min, at an intensity not higher than 2 mA; and thereafter irradiating, with UV light for 5 to 30 min at a power of 3 to 30 mW/cm07-11-2013
20130184673SYSTEMS AND METHODS FOR THERAPEUTIC ELECTRICAL STIMULATION - A patch for a therapeutic electrical stimulation device includes a shoe connected to the first side of the patch, the shoe including a body extending in a longitudinal direction from a first end to a second end, and having first and second surfaces, the first end of the shoe defining at least two ports, and the first surface of the shoe defining a connection member. The patch also includes at least one conductor positioned in the ports of the first end of the shoe. The shoe is configured for sliding insertion into a receptacle defined by a controller so that the conductor is connected to the controller to deliver electrical current from the controller, through the conductor, and to the electrodes, and the connection member is at least partially captured by a detent defined by the controller in the receptacle to retain the shoe within the receptacle.07-18-2013
20130184674TREATING CANCER USING ELECTROMAGNETIC FIELDS IN COMBINATION WITH PHOTODYNAMIC THERAPY - A light generating circuit is implanted in a subject's body and aimed at a target region such as a tumor. A photosensitizer is introduced into the target region, and an AC electric field is induced in the region. The field causes the light generating circuit to generate light, which activates the photosensitizer; and at certain field strengths and frequencies, the field itself has a beneficial effect. The beneficial effects of the field and the activated photosensitizer are thereby obtained simultaneously.07-18-2013
20130190715COMBINATION THERAPY WITH LOW DOSAGE STRENGTH IMIQUIMOD AND PHOTODYNAMIC THERAPY TO TREAT ACTINIC KERATOSIS - This disclosure is directed to the use of complementary or combination photodynamic therapy and topical therapy with a lower dosage strength imiquimod formulation for treating actinic keratosis.07-25-2013
20130190716NERVE TREATMENT SYSTEM - A method of treatment includes delivering an agent into a patient, and providing energy inside the patient so that the energy can interact with the agent to treat a nerve. A system for treatment includes a source of agent for delivery into a patient, and an energy source for providing energy inside the patient so that the energy can interact with the agent to treat a nerve.07-25-2013
20130197473Method and Apparatus for Skin Cancer Thermal Therapy - An apparatus for treatment of soft tissue includes a source of radiation, a handpiece which is adapted to transmit radiation emitted from the source of radiation to a region of soft tissue, resulting in irradiated soft tissue, said handpiece being positioned adjacent to or in contact with said soft tissue region, a grid element adapted to hold at least one temperature sensor in contact with or embedded in said region of soft tissue, and a microprocessor, which converts a signal from the at least one temperature sensor into a measure of damage produced in at least two components of the irradiated soft tissue, said components comprising at least one normal tissue component and at least one malignant, hypertrophic, diseased, or unwanted component.08-01-2013
20130211371FORMULATIONS AND METHODS OF TREATMENT OF SKIN CONDITIONS - A liquid or ointment formulation for the treatment of a skin condition associated with leukocyte accumulation in the skin includes a therapeutic compound selected to reduce leukocyte accumulation in the skin and an aqueous solution of an organic solvent. The organic solvent increases skin permeability. A method of treating a skin condition associated with leukocyte accumulation in the skin includes the steps of applying topically a liquid formulation of a photosensitizer to a skin lesion of a patient afflicted with the skin condition and exposing the skin lesion to a light source.08-15-2013
20130226135METHOD AND APPARATUS FOR ELECTROTHERAPY DRUG DELIVERY - The present invention is directed to a method and apparatus for an electrotherapeutic system including a first and second electrode. Each electrode includes a respective resistance wherein during operation of the electrotherapeutic system, an electrochemical reaction involving one or both of the electrodes varies the respective resistance of at least one of the electrodes.08-29-2013
20130226136Molecules for the Photodynamic Treatment of Tumors and Hyperplasias - This invention relates to pharmaceutical compositions comprising a sulfonated biological precursor of thymidine, such as a precursor of 4-thiothymidine (4-TT), and their use in the photodynamic treatment of skin hyperplasias, including cancer, psoriasis, actinic keratosis and keloids, by topical or systemic administration.08-29-2013
20130231632TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES USING GENE THERAPY - Provided herein are compositions and methods for treating and/or preventing neurodegenerative disease, such as Alzheimer's disease. In particular aspects, compositions administered herein encode a cellular immune response element. The compositions may be prepared and administered in such a manner that the cellular immune response element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain cellular immune response element genes.09-05-2013
20130245598PHOTOACTIVE VITAMIN NANOPARTICLES FOR THE TREATMENT OF CHRONIC WOUNDS - The preparation and use of photosensitizer-containing nanoparticles including photoactive vitamin-containing nanoparticles as photodynamic antimicrobial agents are disclosed for tissue repair including the treatment of chronic wounds.09-19-2013
20130253471Methods and Apparatus for Treating Contrast Nephropathy - Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation of electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.09-26-2013
20130274704AUGMENTED COGNITIVE TRAINING - The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents.10-17-2013
20130281967APPARATUS AND METHOD FOR TREATING A NEUROMUSCULAR DEFECT - One aspect of the present disclosure relates to a treatment probe comprising an elongated body member and a needle portion. The elongated body member can have a proximal end portion and a distal end portion. The needle portion can be connected to the distal end portion. The needle portion can include at least one electrode and at least one fluid port. The at least one electrode and the at least one fluid port can be configured to deliver electrical energy and a tumescent fluid, respectively, so that superficial tissue planes overlying a target nerve are protected from inadvertent heat damage as a result of application of electrical energy to a target nerve.10-24-2013
20130281968Irreversible Electroporation using Nanoparticles - The present invention provides methods, devices, and systems for in vivo treatment of cell proliferative disorders. The invention can be used to treat solid tumors, such as brain tumors. The methods rely on non-thermal irreversible electroporation (IRE) to cause cell death in treated tumors. In embodiments, the methods comprise the use of high aspect ratio nanoparticles with or without modified surface chemistry.10-24-2013
20130289520TARGETED AND LIGHT-ACTIVATED CYTOSOLIC DRUG DELIVERY - The present invention provides methods and compositions for highly precise spatial and temporal control over cytosolic delivery of compounds, in particular, those compounds that would otherwise be cell-impermeable. Among other things, the present invention provides a composition for targeted drug delivery comprising a nanoparticle, a targeting moiety specific for a cell type of interest, a light-activated drug delivery system, wherein the nanoparticles are associated with the targeting moiety and the light-activated drug delivery system.10-31-2013
20130304019PHOTODYNAMIC THERAPY SYSTEM, DEVICE AND ASSOCIATED METHOD OF TREATMENT - As one example, a photodynamic therapy system can include a flexible panel comprising a plurality of light sources distributed across a conformable light delivery surface thereof. The plurality of light sources can be configured to provide a treatment light to achieve a desired therapeutic effect at a predetermined distance from the light delivery surface. The system can also include a spacer configured at the light delivery surface to position the light delivery surface at the predetermined distance from a treatment area of a patient.11-14-2013
20130317475SUBSTITUTED DIBENZONAPHRACENES - The present invention relates to substances, to electroluminescent devices comprising these substances, and to the use thereof.11-28-2013
20130338626PHOTOPATTERNING OF SKIN - Methods and systems for treating skin for aesthetic or health purposes are described. According to various embodiments, photoresponsive materials and light are delivered in a controlled fashion to produce a patterned distribution of a material in the skin.12-19-2013
20130338627FIBER ARRAY FOR OPTICAL IMAGING AND THERAPEUTICS - The present invention relates to the field of optical imaging and therapeutics. More particularly, embodiments of the present invention provide minimally-invasive Fiberoptic Microneedle Devices (FMDs) for light-based therapeutics, which physically penetrate tissue and deliver light directly into the target area below the skin surface. Embodiments of the invention enable depth-selective and deep photothermal therapeutics and include methods of treating cancer, methods of re-shaping or removing adipose tissue, and methods of delivering drugs or co-delivering drugs and energy to selected tissue.12-19-2013
20130345661Skin Treatment Device - A device and methods for increasing the permeability of the skin's surface to fluid and/or drug delivery is described. The device comprises an abrasive media to remove the outer layer of the stratum corneum, while at the same time applying an electric current that stimulates the skin under the stratum corneum, and delivers fluids from a supply reservoir. The device may also have a vacuum function which evacuates fluid and skin debris from the surface of the skin and delivers the evacuated fluid and skin debris to a waste (or collection) container.12-26-2013
20140012224Targeted hollow gold nanostructures and methods of use - Provided are novel nanostructures comprising hollow nanospheres (HGNs) and nanotubes for use as chemical sensors, molecular specific photothermal coupling agents, and photothermal ablation compounds. The nanostructures can be used in electromagnetic radiation-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region.01-09-2014
20140025033Non-Invasive Fat Reduction by Hyperthermic Treatment - The present disclosure relates systems and methods for tissue remodeling, that ameliorate fat deposits by disrupting adipocytes through low-temperature extended treatment time approaches, in conjunction with selective treatment and/or localized cooling of the treatment site to prevent or minimize damage to non-target tissues.01-23-2014
20140046289METHOD FOR THE TREATMENT OF ACNE - This application is directed to a method of treating a patient with acne by applying a photodynamic agent to skin having acne lesions, waiting at least 12 hours, and then exposing the skin to which the photodynamic agent has been applied to light that causes an activation reaction.02-13-2014
20140046290SYNTHESIS OF 2-(4-AMINOPHENYL)BENZOTHIAZOLE DERIVATIVES AND USE THEREOF - The present invention provides a photodynamic therapy to a patient having at least one tumor comprising the steps of: administering a compound of formula 6 (wherein R02-13-2014
20140088548METHOD AND EXTERNAL PREPARATION FOR LYMPHATIC SLIMMING - The present invention provides a set of body slimming compositions, for application to a body before irradiating the body with a far-infrared ray in an atmosphere of 50° C. or thereabout. The slimming composition set includes a first external composition containing a cosmetic base, a Bacillus-fig-soybean fermented liquor, a Bacillus-Monascus-angelica-soybean fermented liquor, a Bacillus-longan-soybean fermented liquor, orizanol, tocopheryl acetate, macadamia nut oil, and glucosyl hesperidine, and a second external composition containing a cosmetic base, a Bacillus-persimmon-soybean fermented liquor, a 03-27-2014
20140128836SAFE DEVICE FOR IONTOPHORETIC DELIVERY OF DRUGS - Provided is a device for iontophoretic delivery of a drug to or into a tissue, including an arrangement that prevents operation of the device at a current density that is higher than a predetermined value, the arrangement including first means responsive to a first data item, indicative of the surface area through which the current is to pass, as to set the maximal current allowed at the surface area indicated by the data item. Also provided is a method for iontophorectivally administering drug to or into a tissue, including determining a maximal allowed level of current density and preventing application of current density above the maximal allowed level.05-08-2014
20140188071Cold Plasma Electroporation of Medication and Associated Methods - A method and device to apply a cold plasma to a substance at a treatment surface of a patient to cause electroporation of the substance into cells of the patient. The substance can be previously applied to the treatment surface. Alternatively, the substance can be placed in a foam-like material within a tip that passes the cold plasma from the cold plasma device to the treatment area. The tip can be a cannula device with an aperture at the distal end. The cannula device can also have apertures along a portion of the length of the cannula device.07-03-2014
20140288527PROCESS AND SYSTEM FOR IONTOPHORETIC WRINKLE REDUCTION - A method and system for wrinkle reduction. The method includes the steps of positioning and applying a patch to skin of a consumer and adhesively securing the patch to the skin. A chemical composition on the patch includes both active ingredients and adhesive. A pair of electrodes are connected to a battery-driven, microprocessor-based controller. A current is applied through the electrodes in the patch for a selected lime. The chemical composition in the patch is propelled into the consumer through use of the current in order to relax the skin or the consumer. The patch is removed and any residue of the chemical composition is massaged into the skin.09-25-2014
20140309613METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AN OCULAR DISEASE IN A SUBJECT - The present invention relates to a method for treating an ocular disease in a subject comprising the steps consisting of i) delivering a pharmaceutical composition formulated with a therapeutic nucleic acid of interest into the suprachoroidal space of the diseased eye and ii) exposing the region where the pharmaceutical composition was delivered to an electrical field.10-16-2014
20140316372DEVICE FOR THE TREATMENT OF AN OCULAR DISEASE - An electrode device having an insertion part (10-23-2014
20140358116METHODS FOR DELIVERING AN ANTI-CANCER AGENT TO A TUMOR - Described herein are methods for delivering an anti-cancer agent to a tumor in a subject. The method involves 12-04-2014
20150032083METHODS FOR IONTOPHORETICALLY TREATING NAUSEA AND MIGRAINE - Methods for treating nausea and migraine by iontophoretically administering triptan compounds are provided.01-29-2015
20150112300METHOD FOR ENHANCED TRANS-TISSUE DELIVERY OF THERAPEUTIC SUBSTANCES - A method of enhanced trans-tissue delivery of therapeutic substances including; placing an electrode in proximity to human or animal tissue covered with material of sufficient concentration of such substances; applying a voltage signal to generate plasma, preferably Dielectric Barrier Discharge in Air, between the tissue and the electrode.04-23-2015
20160175148INTRAOCULAR DELIVERY OF BIOACTIVE MOLECULES USING IONTOPHORESIS06-23-2016
20170231920POSITIVELY CHARGED LIPOSOMES AS LIPOPHILIC MOLECULE CARRIERS08-17-2017

Patent applications in class Enhanced absorption of therapeutic material internally using iontophoretic treatment

Website © 2023 Advameg, Inc.